I recently had the privilege of speaking at the Advances in Rheumatology and Technologies Symposium (ARTS), held in Chicago ...

Fibromyalgia was considered a comorbidity rather than a rheumatic disease, but was present in about 10% of patients. Other ...

Medical board-style questions created by AI and large language models were often grammatically correct but factually ...

Tonmya demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT studyTreatment ...

KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid ...

The current recommended urine protein to creatinine ratio is arbitrary, and a lower bar would capture more lupus nephritis ...

Data from the Phase 1 CARLYSLE study in severe refractory systemic lupus erythematosus (srSLE) suggests obe-cel is well tolerated with no ICANS ...

Danve and colleagues are working to change that. Their new study, published in Rheumatology Advances in Practice, tested an ...

The trainees who successfully complete this program will be fully trained and equipped to function as clinical rheumatologists, clinician educators or clinician scientists, depending on the individual ...

The Lupus Foundation of America (LFA) and its funded researchers will unveil the latest advances in patient-centered research ...

Tonix Pharmaceuticals (TNXP) presented data on Tonmya, which was investigated as TNX-102 SL, at the 2025 American College of Rheumatology ...